2.1.1.366	1-methyl-5H-[1,2,4]triazolo[4,3-a][3,1]benzoxazine	SETDB1-TTD inhibitor, binds to the acetyl lysine (Kac) pocket of the SETDB1-TTD	284492	
2.1.1.366	1-[(3,4-dimethoxyphenyl)methyl]-4-[[2-(trifluoromethyl)-7H-pyrrolo[2,3-b]pyridin-7-yl]methyl]piperidin-4-ol	peptidecompetitive SETDB1 inhibitor, decreases SETDB1/ESET levels without changing the mRNA levels (FRET) and exerts noticeable inhibitory effects on H3K9 trimethylation. Induces neuronal cytotoxicity at 0.1 mM	284514	
2.1.1.366	2-([5-[4-(benzyloxy)phenyl]-1-methylpiperidin-3-yl]amino)-3-(prop-2-en-1-yl)-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one	SETDB1-TTD inhibitor, inhibits the interaction of H3 peptide with the SETDB1-TTD	284702	
2.1.1.366	3,3-dimethyl-1-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]butan-1-one	SETDB1-TTD inhibitor, very weak binding in the aromatic cage of the dimethyl lysine (Kme2) pocket of the SETDB1-TTD	284944	
2.1.1.366	5-[(prop-2-en-1-yl)oxy]-2-(pyrrolidin-1-yl)quinoline	SETDB1 SET domain inhibitor, inhibits SETDB1 activity and H3K9me3 expression, and improves motor function and neuropathological symptoms with minimal toxicity in mouse HD models	285584	
2.1.1.366	7-chloro-2-[3-(dimethylamino)propyl]-1-(3-ethoxyphenyl)-1,2,3a,9a-tetrahydro[1]benzopyrano[2,3-c]pyrrole-3,9-dione	peptidecompetitive SETDB1 inhibitor, decreases H3K9me3 levels and shows neuronal effects without cytotoxicity	285747	
2.1.1.366	ATF7IP	SETDB1 partner protein. SETDB1 and the SETDB1:ATF7IP complex efficiently catalyze both monomethylation and dimethylation of H3K9 peptide substrates. The activity of the binary complex is 4fold lower than SETDB1 alone	252751	
2.1.1.366	N-[(furan-2-yl)methyl]-1-[(3S)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]piperidine-4-carboxamide	SETDB1-TTD inhibitor, binds in the aromatic cage	286484	
2.1.1.366	N-[2-(diethylamino)ethyl]-2-([5,7-dimethyl-6-[(2-methylphenyl)methyl][1,2,4]triazolo[1,5-a]pyrimidin-2-yl]sulfanyl)acetamide	competitive SETDB1 inhibitor, decreases H3K9me3 levels and shows neuronal effects without cytotoxicity	286499	
2.1.1.366	N-[[1,1'-bi(cyclohexan)]-4-yl]-6-methoxy-7-[3-(piperidin-1-yl)propoxy]-2-[4-(propan-2-yl)-1,4-diazepan-1-yl]quinazolin-4-amine	competitive inhibition, the inhibitor docks in the Tudor domain	286659	
2.1.1.366	N-[[2-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)cyclohexyl]methyl]acetamide	SETDB1-TTD inhibitor, binds in the aromatic cage of the Kac pocket of the SETDB1-TTD. It displayed weak binding by SPR and ITC	286661	
2.1.1.366	N2-(3'-[[4-(4-butylpiperazin-1-yl)pyridine-2-carbonyl]amino][1,1'-biphenyl]-4-carbonyl)-6-pyrrolidin-1-yl-L-norleucinamide	SETDB1-TTD inhibitor, shows competitive inhibition and docked between the Tudor 2 and 3	286714	
2.1.1.366	N2-(3'-[[4-(4-butylpiperazin-1-yl)pyridine-2-carbonyl]amino][1,1'-biphenyl]-4-carbonyl)-N6,N6-dimethyl-L-lysinamide	SETDB1-TTD inhibitor, shows competitive inhibition and docks between the Tudor 2 and 3 domains	286715	
2.1.1.366	N2-(3'-[[4-(4-methylpiperazin-1-yl)pyridine-2-carbonyl]amino][1,1'-biphenyl]-4-carbonyl)-6-pyrrolidin-1-yl-L-norleucinamide	SETDB1-TTD inhibitor, shows competitive inhibition and docks between the Tudor 2 and 3 domains	286716	
2.1.1.366	N2-[3'-[(4-[4-[3-(dimethylamino)propyl]piperazin-1-yl]pyridine-2-carbonyl)amino][1,1'-biphenyl]-4-carbonyl]-6-pyrrolidin-1-yl-L-norleucinamide	SETDB1-TTD inhibitor, shows competitive inhibition and docks between the Tudor 2 and 3 domains	286725	
2.1.1.366	N2-[3'-[(4-[4-[3-(dimethylamino)propyl]piperazin-1-yl]pyridine-2-carbonyl)amino][1,1'-biphenyl]-4-carbonyl]-N6,N6-dimethyl-L-lysinamide	SETDB1-TTD inhibitor, shows competitive inhibition and docks between the Tudor 2 and 3 domains	286726	
2.1.1.366	N4-[6-(dimethylamino)hexyl]-N2-[5-(dimethylamino)pentyl]-6,7-dimethoxyquinazoline-2,4-diamine	SETDB1-TTD inhibitor, shows competitive inhibition and docks between the Tudor 2 and 3 domains	286744	
2.1.1.366	N6,N6-dimethyl-L-lysyl-L-serylthreonyl-N-([4-[2-(acetamidomethyl)cyclohexyl]-4H-1,2,4-triazol-3-yl]methyl)glycinamide	-	286746